1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Key Pharma News 15 FEBRUARY 2016

Key Pharma News 15 FEBRUARY 2016

  • February 2016
  • -
  • Espicom Business Intelligence
  • -
  • 30 pages

Industry Trend Analysis - Ownership Of Digital Reputation Crucial With Growing Compassionate Use Demand
Industry Trend Analysis - GSK Making Gains In Customising Novel Oncology Division
Industry Brief - MedinCell/Sandoz Collaborate To Develop Long-Acting Injectable Products
Industry Trend Analysis - Gilead To Target Transformational Opportunities
Industry Brief - AstraZeneca Completes Majority Equity Stake Purchase Of Acerta
Industry Trend Analysis - Oncology Performance Validates Strong Focus
Industry Trend Analysis - Market Conditions Challenge Sandoz But Biosimilars Provide Optimism
Industry Trend Analysis - Growing Strength Of Roche's Immunology Division Underlined By FY15 Results
Industry Trend Analysis - NGS Portfolio Development To Benefit Diagnostics And Pharmaceuticals
Industry Trend Analysis - Diversification Key To Overcoming Tecfidera Reliance
Industry Trend Analysis - Successful Integration And Restructuring Essential For Lannett's Future Prospects
Industry Trend Analysis - Cabozantinib Will Encounter Toughening Market Environment Despite Swift Entry
Industry Brief - Tagrisso Approved In EU
Industry Brief - FDA Approves Merck's Fixed-Dose HCV Regimen
Industry Brief - Health Canada Approves Vertex' Orkambi To Treat CF Patients
Industry Brief - FDA Approves Takeda's Dexilant SoluTab
Industry Brief - Sun Launches Imatinib Mesylate In US
Industry Trend Analysis - Breakthrough Designation For Rapastinel Enhances Competitive Position
Industry Trend Analysis - Gilead In Strong Position To Counter TAF Lawsuit
Industry Brief - Health Canada Approves Haemophilia Treatment, Kovaltry
Industry Trend Analysis - CMS Biosimilar Reimbursement Rule Highlights Need For Interchangeability Guidance
Industry Trend Analysis - FDA Budget Request Takes Aim At Pay-For-Delay Agreements
Industry Trend Analysis - Pfizer Edges Towards US Biosimilar Infliximab Dominance
Industry Trend Analysis - Combination Approach Increases Commercial Scope For Small Oncolytic Immunotherapy Developers
Industry Trend Analysis - Direct Jakafi Competition Prospects In Myelofibrosis Waning
Industry Trend Analysis - Digital Healthcare Partnerships Offer Expedited Development Potential
Industry Brief - Positive Top-Line Results Announced In Repatha Phase III GAUSS-3 Trial

Table Of Contents

Key Pharma News 15 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.